Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
187 participants
OBSERVATIONAL
2010-07-29
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There are 3 parts to this study. In Part 1, participants will complete 1 set of interviews and questionnaires about GIST symptoms. In Part 2, the importance of some symptoms to patients with GIST will be rated by doctors, nurses, patients, and family caregivers. In Part 3, participants will complete questionnaires about GIST symptoms over 1 year.
You are being asked to take part in Part 3 of the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study
NCT05440357
Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer
NCT06157216
A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
NCT02776878
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
NCT00812240
Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ
NCT06739161
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If you agree to take part in this study, you will complete questionnaires about symptoms you are having. You will be asked to fill these out 1 time a week during the first 2 months after surgery, 1 time a week during the first 3 months of a new therapy, and every 2 weeks at other times. The questionnaire will ask you to rate how severe your symptoms are and how the symptoms effect the activities of your daily life. The symptom questionnaire should take about 5 minutes to complete. You will complete the questionnaire during the first study visit and at your regular clinic visits.
Between clinic visits, you will be called every 1-2 weeks to complete the questionnaire using an automated telephone system. You can decide what time is most convenient for the automated phone system to call you. If you are not available when the automated system calls, it will call you again at a later time. If you are not reached by the automated phone system after several tries, the study staff will call you. You will be given a secure user name and identification number to use with the automated phone system. The study staff will teach you how to use the automated phone system.
At the clinic visit closest to 3 months after you start the study, you may be seen by a research staff member a second time 1 to 3 days after you completed the symptom questionnaire and asked to fill out the symptom questionnaire again. The research staff member may contact you by phone prior to this clinic visit to arrange times to meet you for the 2 assessments.
Quality-of-Life/Demographic Questionnaires:
At the first visit and the regular clinic visits, you will also rate your overall quality-of-life. This should take about 1 minute to complete.
At the first visit, you will also be asked some demographic questions (such as your age and marital status). Answering these questions should take about 1 minute.
Opinion Questionnaire:
If you are 1 of the first 40 patients enrolled in the study, you will be asked questions about your opinion of the symptom questionnaire at the clinic visit closest to 3 months after you start the study. For example, you will be asked if the symptom questionnaire was easy to understand and complete, and if there were any other questions that should be included. The study staff will use your opinion to decide if changes should be made to the questionnaire or if important symptom questions are missing from the questionnaire. This questionnaire should take about 5 minutes to complete.
Length of Study:
You will be on study for 1 year. You will be off study after you complete the last symptom questionnaire.
This is an investigational study.
Up to 188 participants will take part in this study. Up to 150 participants will be enrolled in Part 3 of this study. All will be enrolled at MD Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1
Patient interview and developmental questionnaires
Questionnaires
10 minutes to complete 3 questionnaires for development of MDASI-GIST
Interview
Each interview will take approximately 30 minutes.
Part 2
Content Expert Panel (doctors, nurses) + Patients and Caregivers Questionnaire Development
Questionnaires
10 minutes to complete 3 questionnaires for development of MDASI-GIST
Part 3
Patient MDASI-GIST Questionnaire
MDASI-GIST Questionnaire
Every 4 weeks for one year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaires
10 minutes to complete 3 questionnaires for development of MDASI-GIST
Interview
Each interview will take approximately 30 minutes.
MDASI-GIST Questionnaire
Every 4 weeks for one year
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Ability to speak and read English (All participants)
3. Residing where IVR service is available (Part 3, Patient only)
4. Diagnosis of GIST confirmed by pathological analysis (Patient only)
5. Starting new treatment (either surgical or medical) and planning to be followed at M.D. Anderson Cancer Center (Part 3, Patient only)
6. Written consent to participate (All participants)
7. At least 3 months from start of initial treatment (surgical or medical) for GIST (Part 2, Patient only)
8. Family caregiver also willing to receive packet for expert panel participation (Part 2, Patient only)
9. Physician or nurse with at least 5 years experience caring for patients with GIST (Professional expert only)
10. At least one publication in the last 5 years dealing with GIST (Physician professional expert only)
11. Identification as a family caregiver by a patient with GIST (Family caregiver only)
12. Patient also willing to receive packet for expert panel participation (Family caregiver only)
Exclusion Criteria
2. Diagnosis of active psychosis or severe cognitive impairment as determined by primary physician (Patient only)
3. Active treatment (systemic drug therapy or radiation therapy) for a second malignancy (Patient only)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Loretta A. Williams, PhD, MSN
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-0267
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.